Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin
The Journal of Allergy and Clinical Immunology: In Practice · 2023-05 · 11 (5) · 1421-1428
DOI: 10.1016/j.jaip.2023.03.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-05. Verfasst von Donald Y M Leung und 16 weiteren Autor:innen. Beteiligte Einrichtung: National Jewish Health, Denver, Colo. Electronic address: Leungd@njhealth.org. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Sanofi.
Abstract (Originalsprache)
BACKGROUND: Atopic dermatitis (AD) skin lesions are associated with oozing, bleeding, and erythema. This suggests that AD is associated with vascular changes. Dupilumab is an antibody to the alpha subunit of IL-4 receptor that demonstrates strong efficacy in the treatment of AD. IL-4 is known to reduce the permeability barrier function of vascular endothelium. OBJECTIVE: To examine the effects of dupilumab on vascular barrier function in AD skin. METHODS: Using proteomic analysis, we evaluated the plasma protein composition in skin tapes of lesional and nonlesional skin of adults and adolescents with moderate to severe AD over the course of a 16-week treatment with dupilumab and compared those with matched healthy subjects. RESULTS: At baseline, 115 plasma proteins were detected in AD skin and globally increased (1.5-fold or greater) compared with healthy skin. Functionally, these proteins included immunoglobulins, proteins involved in the coagulation process, enzymes, protease inhibitors, transport proteins, acute-phase proteins, complement proteins, and other pleiotropic proteins. Noteworthy, fibrinogens, fibronectin, and heme-binding proteins haptoglobin and hemopexin were among the top proteins originating from plasma and were increased in AD lesional versus healthy skin at baseline (P < .0001). Dupilumab treatment resulted in significantly reduced levels of plasma proteins in AD skin (P < .0001), with most dropping to levels seen in healthy skin or no longer detectable at week 16. CONCLUSIONS: Inhibition of IL-4/IL-13 action by dupilumab significantly reduces the efflux of plasma proteins into AD skin. Several of these proteins, such as fibrinogens and fibronectin, are known to enhance Staphylococcus aureus colonization and are associated with AD skin severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Jewish Health, Denver, Colo. Electronic address: Leungd@njhealth.org.
- Innovaderm Research, Montreal, Quebec, Canada.
- Advanced Clinical Biosystems Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, Calif.
- National Jewish Health, Denver, Colo.
- Sanofi, Bridgewater, NJ.
- Regeneron Pharmaceuticals, Inc, Tarrytown, NY.
Förderung
- Sanofi
Zitieren
APA
Leung, D. Y. M., Bissonnette, R., Kreimer, S., Berdyshev, E., Bafna, S., Lyubchenko, T., Richers, B. N., Garcia, S., Ramirez-Gama, M., Hall, C. F., Xiao, O., Taylor, P., Boguniewicz, M., Levit, N. A., Agueusop, I., Zhang, A., & Goleva, E. (2023). Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin. The Journal of Allergy and Clinical Immunology: In Practice, 11(5), 1421-1428. https://doi.org/10.1016/j.jaip.2023.03.020
Vancouver
Leung DYM, Bissonnette R, Kreimer S, Berdyshev E, Bafna S, Lyubchenko T, et al. Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(5):1421-1428. doi:10.1016/j.jaip.2023.03.020
BibTeX
@article{Leung2023,
author = {Leung, Donald Y M and Bissonnette, Robert and Kreimer, Simion and Berdyshev, Evgeny and Bafna, Shantanu and Lyubchenko, Taras and Richers, Brittany N and Garcia, Shannon and Ramirez-Gama, Marco and Hall, Clifton F and Xiao, Olivia and Taylor, Patricia and Boguniewicz, Mark and Levit, Noah A and Agueusop, Inoncent and Zhang, Annie and Goleva, Elena},
title = {Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
volume = {11},
number = {5},
pages = {1421--1428},
doi = {10.1016/j.jaip.2023.03.020}
}
EUVIMED